Half Year 2025 Roche Holding AG Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Richard Vosser - JPMorgan Chase & Co - Analyst : Thanks, Bruno. Hopefully, you can hear me. A couple of questions, please. First question, just on Vabysmo. Could you give a little bit more color on your expectations for the second half? I think we could see increased funding at the foundations under matching program. So how are you thinking about a potential of a reacceleration of the product in the market for branded products in the second half? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 24, 2025 / 12:00PM, ROG.S - Half Year 2025 Roche Holding AG Earnings Call And then the second question, just on Columvi and trials -- the first-line trials in DLBCL. Obviously, the FDA panel at the end, the FDA talked about proportion of patients in trials in the US So just wondering if you could reassure us around the enrollment into the first-line trials that they have sufficient US patients. Obviously, it's against standard of care for the US with Polivy in the base. So that's not a problem, but just the US proportion of patients. Teresa Graham - Roche Holding AG - Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals Great. So let's start with second half expectations. So as I mentioned, we are expecting roughly 20% growth for Vabysmo in the second half. This is, of course, subject to the caveats that the US environment can be a little bit hard to predict. While we saw a 7% contraction of the overall market in ophthalmology in the US in the first half. What we did see is that Vabysmo continued to grow 3% within that branded space. We are still at 60% in growing naive patients. And so the momentum for Vabysmo continues. So as new patients do come to seek treatment, I think we would continue to see Vabysmo take patient share. In terms of the number of patients for our first-line DLBCL trials. So clearly, US participation in trials is a key issue that everybody is looking at. We are as well for all of our key clinical trials. Each clinical trial that we run is run and these are large global multicenter studies, and we are working very closely with global regulators, including the FDA to ensure that we're enrolling patient populations that are representative. And so we are very much we are very much working to make sure that our trials are -- have sufficient US representation and I believe that we are on a good path.

Question: Richard Vosser - JPMorgan Chase & Co - Analyst : No, I'll leave it there. Leave it to someone else. Thank you very much.